Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Certolizumab pegol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    96 result(s) found for: Certolizumab pegol. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-002027-16 Sponsor Protocol Number: RPCG06B2433 Start Date*: 2006-12-12
    Sponsor Name:UCB AE
    Full Title: Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subseq...
    Medical condition: Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-018027-33 Sponsor Protocol Number: RA0043 Start Date*: 2024-08-30
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A multicenter, open-label study to assess the pharmacokinetics, safety and efficacy of certolizumab pegol in children and adolescents with moderately to severely active polyarticular-course juvenil...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002716-26 Sponsor Protocol Number: C87088 Start Date*: 2008-01-22
    Sponsor Name:UCB Celltech
    Full Title: A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal ...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Prematurely Ended) HU (Completed) LV (Completed) EE (Completed) IT (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005025-20 Sponsor Protocol Number: CR0012 Start Date*: 2018-03-21
    Sponsor Name:UCB Biosciences, Inc.
    Full Title: An open-label, multicenter study to assess the safety of certolizumab pegol in children and adolescents with active Crohn's Disease who completed C87035 or who were terminated from C87035 when the ...
    Medical condition: Crohn´s Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000830-38 Sponsor Protocol Number: C87080 Start Date*: 2008-10-07
    Sponsor Name:UCB Pharma S.A.
    Full Title: A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthriti...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) AT (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002326-63 Sponsor Protocol Number: CDP870-050 Start Date*: 2005-09-21
    Sponsor Name:UCB Celltech
    Full Title: A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    10039073
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-003977-25 Sponsor Protocol Number: C87043 Start Date*: 2007-01-31
    Sponsor Name:UCB S.A
    Full Title: A phase III B multicentre open label 54 weeks clinical trial evaluating certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF alpha) on endoscopic a...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000337-13 Sponsor Protocol Number: PreCePra Start Date*: 2013-05-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (P...
    Medical condition: Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002629-30 Sponsor Protocol Number: CDP870-051 Start Date*: 2006-01-30
    Sponsor Name:UCB Inc
    Full Title: A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptom...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    10039073
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-001913-41 Sponsor Protocol Number: C87085 Start Date*: 2007-12-12
    Sponsor Name:UCB Celltech
    Full Title: A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha mono...
    Medical condition: Crohn`s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) HU (Completed) LV (Completed) BE (Completed) EE (Completed) IT (Completed) DE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003871-11 Sponsor Protocol Number: C87065 Start Date*: 2007-02-06
    Sponsor Name:UCB Pharma S.A.
    Full Title: An open-label, multi-center trial to examine the long term safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease who have fai...
    Medical condition: The trial aims to examine the long term safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease who have failed tapering of cor...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003513-28 Sponsor Protocol Number: PS0005 Start Date*: 2015-03-27
    Sponsor Name:UCB Biopharma, SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group Study Followed by a Dose-blind Period and Open Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004399-42 Sponsor Protocol Number: C87037 Start Date*: 2015-03-05
    Sponsor Name:UCB Japan Co., Ltd.
    Full Title: A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With...
    Medical condition: Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-005288-86 Sponsor Protocol Number: C87077 Start Date*: 2009-03-18
    Sponsor Name:UCB Pharma S.A.
    Full Title: A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotr...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001894-41 Sponsor Protocol Number: AS0006 Start Date*: 2015-10-16
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X-RAY ...
    Medical condition: ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X-RAY EVIDENCE OF ANKYLOSING SPONDYLITIS (AS) AND OBJECTIVE SIGNS OF INFLAMMATION
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10076297 Non-radiographic axial spondyloarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-003239-21 Sponsor Protocol Number: C87091 Start Date*: 2008-02-05
    Sponsor Name:UCB PHARMA S.A.
    Full Title: A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when t...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004104-37 Sponsor Protocol Number: C87042 Start Date*: 2006-03-23
    Sponsor Name:UCB S.A.
    Full Title: A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab fragment ...
    Medical condition: Patients with Crohn's Disease with prior loss of response or intolerance to infliximab
    Disease: Version SOC Term Classification Code Term Level
    10011401
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) AT (Completed) SE (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001729-24 Sponsor Protocol Number: C87046 Start Date*: 2006-10-18
    Sponsor Name:UCB S.A.
    Full Title: Open label long term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy with certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF) in...
    Medical condition: Patients with Crohn's disease and having completed C87042 study.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) AT (Completed) FR (Completed) SE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005309-28 Sponsor Protocol Number: APHP200031 Start Date*: 2023-04-07
    Sponsor Name:Assistance Publique des Hôpitaux de Paris
    Full Title: Efficacy of certolizumab in women with unexplained recurrent implantation failure: a double-blind randomized controlled trial - CERTIFY
    Medical condition: Adult women with recurrent implantation failures
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003870-88 Sponsor Protocol Number: RPCE06G2013 Start Date*: 2006-11-27
    Sponsor Name:UCB Pharma S.A.
    Full Title: A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease...
    Medical condition: In the present study, the corticosteroid-sparing effect of certolizumab pegol will be assessed in patients with moderate to severe Crohn’s disease who have received initial acute corticosteroid the...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:42:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA